PMID- 21144225
OWN - NLM
STAT- MEDLINE
DCOM- 20110325
LR  - 20181201
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 24
IP  - 6
DP  - 2010 Nov-Dec
TI  - Pioglitazone attenuates allergic inflammation and induces production of 
      regulatory T lymphocytes.
PG  - 454-8
LID - 10.2500/ajra.2010.24.3522 [doi]
AB  - BACKGROUND: Peroxisome proliferator-activated receptor gamma (PPAR-gamma) 
      agonists have been shown to be involved in the regulation of allergic 
      inflammatory responses. The molecular mechanisms by which PPAR-gamma activation 
      inhibits the inflammatory process have not been well understood. METHODS: BALB/c 
      mice received ovalbumin (OVA) sensitization followed by OVA intranasal challenge. 
      Mice in the treatment group received intragastric administration with 
      pioglitazone (PIO; 30 mg/kg) before each OVA challenge. Various allergic 
      responses were then assessed. RESULTS: The frequencies of sneezing and 
      nose-scratching and eosinophil infiltration decreased significantly in the PIO 
      treatment group compared with the OVA group (p < 0.05). The PIO treatment also 
      showed that the levels of nasal cavity lavage fluid interleukin (IL)-5 and sera 
      OVA-specific immunoglobulin E (IgE) were markedly reduced (p < 0.05). PIO 
      significantly increased the expression of Foxp3 mRNA (p < 0.05) and induced 
      production of regulatory T lymphocyte (p < 0.01) compared with the OVA group. 
      CONCLUSION: Given the potent effectiveness shown by PIO, we conclude that 
      PPAR-gamma agonists deserve investigation as potential therapies for human 
      allergic upper airway inflammation.
FAU - Wang, Weihua
AU  - Wang W
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai East Hospital, 
      Tongji University School of Medicine, 150 Jimo Road, Shanghai, China.
FAU - Zhu, Zhenghua
AU  - Zhu Z
FAU - Zhu, Bingwei
AU  - Zhu B
FAU - Ma, Zhaoxin
AU  - Ma Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Foxp3 protein, mouse)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (Interleukin-5)
RN  - 0 (PPAR gamma)
RN  - 0 (RNA, Messenger)
RN  - 0 (Thiazolidinediones)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Animals
MH  - CD4-Positive T-Lymphocytes/drug effects
MH  - Female
MH  - Forkhead Transcription Factors/genetics
MH  - GATA3 Transcription Factor/genetics
MH  - Immunoglobulin E/blood
MH  - Interleukin-5/blood
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - PPAR gamma/*agonists
MH  - Pioglitazone
MH  - RNA, Messenger/analysis
MH  - Rhinitis, Allergic, Perennial/*drug therapy/immunology
MH  - T-Lymphocytes, Regulatory/*drug effects/physiology
MH  - Thiazolidinediones/pharmacology/*therapeutic use
EDAT- 2010/12/15 06:00
MHDA- 2011/03/26 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/03/26 06:00 [medline]
AID - 10.2500/ajra.2010.24.3522 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2010 Nov-Dec;24(6):454-8. doi: 10.2500/ajra.2010.24.3522.